Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 13/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615340 | 0.90 | MCL1 (0.60) | MCL1L3MBTL1ALDH1A1LMNAGLA | |
| SCHEMBL13629420 | 0.87 | MCL1 (0.56) | MCL1L3MBTL1ALDH1A1LMNAGLA | |
| SCHEMBL13615244 | 0.86 | NHERF1 (0.65) | MCL1L3MBTL1ALDH1A1NHERF1HPGD | |
| SCHEMBL10702348 | 0.85 | MCL1 (0.70) | MCL1L3MBTL1ALDH1A1LMNAGLA | |
| SCHEMBL13852823 | 0.82 | MCL1 (0.59) | MCL1L3MBTL1ALDH1A1LMNANHERF1 | |
| SCHEMBL13615288 | 0.81 | HSD17B2 (0.57) | KIF11 | |
| SCHEMBL30229887 | 0.80 | MCL1 (0.63) | MCL1L3MBTL1ALDH1A1LMNAGLA | |
| SCHEMBL13852834 | 0.79 | MCL1 (0.59) | MCL1ALDH1A1LMNAMAPT | |
| SCHEMBL13852835 | 0.79 | HSD17B2 (0.57) | MCL1LMNAMAPTTSHR | |
| SCHEMBL13615137 | 0.79 | LMNA (0.55) | MCL1L3MBTL1ALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | MCL1 790/4885L3MBTL1 3274/4885ALDH1A1 2057/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | MCL1 786/4885L3MBTL1 3262/4885ALDH1A1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.